Greenwich LifeSciences (GLSI) Short term Debt (2019 - 2020)
Greenwich LifeSciences (GLSI) posted Short term Debt of $275154.0 for Q4 2020, down 56.68% on a QoQ basis from $635154.0 in Q3 2020, and down 56.68% year-over-year from $635154.0 in Q1 2020.
Greenwich LifeSciences (GLSI) Short term Debt (2019 - 2020) Analysis & Trends
Greenwich LifeSciences' Short term Debt history runs 2 years deep, the most recent figure standing at $275154.0 for Q4 2020.
- Quarterly Short term Debt fell 56.68% year-over-year to $275154.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $275154.0 (down 56.68% YoY) and the FY2020 annual result came in at $275154.0, down 56.68% from the prior year.
- Short term Debt was $275154.0 for Q4 2020 at Greenwich LifeSciences, down from $635154.0 in the prior quarter.
- Across five years, Short term Debt topped out at $12.0 million in Q3 2019 and bottomed at $275154.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 275,154.00 |
| Sep 30, 2020 | 635,154.00 |
| Dec 31, 2019 | 635,154.00 |
| Sep 30, 2019 | 12.00 Mn |